Hyundai Mobis Co. has come up with an in-house brainwave-based driver monitoring system that can reduce the risk of drowsy driving by up to one-third.
The system, dubbed M.Brain, is a wearable earpiece that continuously detects and analyzes drivers' brain activity.
The company has examined the actual effect of the technology through a pilot study on public buses in Gyeonggi Province over the past year in partnership with the Gyeonggi Research Institute.
According to the findings, drivers who used M.Brain saw their risk of careless driving during after-meal hours, when drowsy driving is most common, drop by up to 30 percent.
M.Brain helped minimize the danger of careless driving by roughly 20% on highways where drowsy driving can lead to multi-car accidents.
When sloppy driving was detected in real-time, the device helped drivers recover attention within 2.3 seconds by blasting an alarm over the speakers and vibrating the seat.
This is nearly three times faster than the 6.7 seconds it took non-M.Brain drivers to regain attention.


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
FedEx Faces Class Action Lawsuit Over Tariff Refunds After Supreme Court Ruling
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Greg Abel’s First Berkshire Hathaway Shareholder Letter Signals Continuity, Caution, and Capital Discipline
Australia Targets AI Platforms With Strict Age Verification Rules
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Nintendo Share Sale: MUFG and Bank of Kyoto to Sell Stakes in Strategic Unwinding
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 



